Abstracts

P10.12 ROLE OF CONDYLOMA ACUMINATA IN INCIDENT HIV INFECTION: A POPULATION-BASED COHORT STUDY IN TAIWAN 2000–2010

1H Zu*, 2Y Chen, 3C Strong, 4C Li, 5W Ko, 6N Ko. Kirby Institute, University of New South Wales, Sydney, 2052, Australia; 2Department of Nursing, National Cheng Kung University, Tainan, 701, Taiwan; 3Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan; 4Department of Public Health, National Cheng Kung University, Tainan, 701, Taiwan; 5Department of Internal Medicine, National Cheng Kung University, Tainan, 701, Taiwan; 6College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.

Introduction The role of Condyloma Acuminata (CA) in incident HIV infection has not been well documented. We aimed to elucidate this relationship by analysing a large national cohort.

Methods Medical claim records 2000–2010 of 1 million individuals randomly selected from the Taiwan National Health Insurance Research Database (NHIRD, approximately 23 million individuals in total) were retrieved. We included all patients treated for CA (PWCs) and patients screened for and confirmed without CA (PWOCs). We matched five patients never screened for CA (PNCs) for every one PWC by year of first CA treatment/first clinical visit, gender and age. PWCs, PWOCs and PNCs were followed from the date of first CA screening and first clinical visit, retrospectively. Endpoint was incident HIV infection. Chi-square test was used to compare socio-demographic characteristics among patients. Characteristics with a P value of <0.1 using univariate Cox regression were entered into a multivariate Cox regression model to calculate adjusted hazard ratio (aHR) of incident HIV infection.

Results We included 1539 PWCs, 1106 PWOCs and 7695 PNCs. The three groups were comparable with respect to age, gender, location and income. HIV incidence was 284.0 (95% CI: 214.9–384.9), 110.6 (95% CI: 41.5–229.7) and 3.8 (95% CI: 0.5–27.2) per 100,000 person-years among PWCs, PWOCs and PNCs, respectively. Compared to PNCs, PWOCs were 66.4 (8.6–310.2) times and PWOCs 33.7 (3.8–303.3) times more likely to have incident HIV infection. Other variables associated with incident HIV infection were being a male (aHR = 10.5, 95% CI: 2.4–46.1), being under 30 years of age (aHR = 3.5, 95% CI: 1.9–5.9) and syphilis diagnosis with treatment before HIV infection (aHR = 4.5, 95% CI: 1.0–19.7).

Conclusion CA is associated with elevated incident HIV infection. HIV risk reduction interventions among patients with CA are warranted.

Disclosure of interest statement This study is funded by the Taiwan Ministry of Science (Project ID: 1030087343). All authors declare no conflict of interest.

P10.11 SERUM ANTIBODY RESPONSES FOLLOWING ANAL AND PENILE INFECTION WITH HUMAN PAPILLOMAVIRUS IN TEENAGE MEN WHO HAVE SEX WITH MEN

1,2H Zu*, 3,4S Tabrizi, 5A Grulich, 1Hocking, 1,5,6C Garland, 1,5C Bradshaw, 1MC Farley†, 1TM Chief†. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia; 4School of Population and Global Health, University of Melbourne, Melbourne, Australia; 6Kirby Institute, University of New South Wales, Sydney, Australia; 7Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia; 8Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Melbourne, Australia; 5Murdoch Childrens Research Institute, Melbourne, Australia; 8Centre for Women’s Health, Gender and Society, University of Melbourne, Melbourne, Australia; 9Central Clinical School, Monash University, Melbourne, Australia; 6Joint Last Authors

Introduction No previous studies have measured HPV seroconversion rates following incident HPV infections of the anus. We examined these in teenage men who have sex with men (MSM).

Methods A cohort of 200 MSM aged 16–20 years were assessed at baseline, 3, 6 and 12 months. At each visit penile and anal swabs were collected for HPV DNA and serum for HPV antibodies for types 6, 11, 16 and 18. Seroconversion was defined as the detection of HPV antibodies following a negative antibody result for the same HPV genotype at baseline.

Results The sero incidence rates for HPV types 6, 11, 16 and 18 were: 18.8, 6.7, 3.9, and 5.8 per 100 person-years respectively. Men who experienced incident anal HPV infections from types 6 or 11 were significantly more likely to develop serum antibodies to the same HPV type than those who experienced incident anal infections from types 16 and 18 (72.7% vs 18.2%, Odds ratio (OR) = 12.0, 95% Confidence interval (CI): 2.5–58.1). However the likelihood to seroconvert did not differ between men who experienced incident penile HPV infections from types 6 or 11 and those who experienced incident penile infections from types 16 or 18 (42.9% vs 20.0%, OR = 3.0, 95% CI: 0.2–53.2). The median time between incident anal HPV infection and seroconversion for HPV 6, 11, 16, and 18 was: 91 days, 38 days, 161 days and 182 days respectively.

Conclusion Serum antibody responses were more likely to occur following anal infections with HPV types 6 and 11 than with types 16 and 18. Seroconversion may occur at a variable number of months after anal HPV infection.

Disclosure of interest statement This investigator initiated study was funded by Merck. Merck had no input into the design, analysis or reporting of the study. CKF has received honoraria from CSL Biotherapies and Merck and research funding from CSL Biotherapies. CKF owns shares in CSL Biotherapies the manufacturer for Gardasil. JSH has received an honorarium from CSL Biotherapies and is an investigator on an Australian Research Council funded project (LP0883831) that includes CSL Biotherapies as a research partner. AEG has received honoraria and funded research from CSL biotherapies, and has received honoraria from Merck. SMG has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has received funding through her institution to conduct HPV vaccine studies for MSD and GSK. SMG is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. None of this relates to this specific work. MYC reported his institution received a grant from Merck Sharp Dohme that supported the conduct of the study. MGL receives grants from Bristol Myer Squibb, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck, Pfizer and Roche which are not related to this project. All other authors have no conflicts of interest.

10.1136/sextrans-2015-052270.439

P10.13 PREVALENCE AND PREDICTORS OF HIGH-RISK ANAL HUMAN PAPILLOMAVIRUS (HPV) TYPES IN THE STUDY OF THE PREVENTION OF ANAL CANCER (SPANC)

1IM Payten*, 2S Tabrizi, 3F Jin, 4BT Templeton, 5RJ Hillman, 6A Comall, 7PS Phillips, 8SM Garland, 9AE Grulich. 1Department of Public Health, National Cheng Kung University, Tainan, 701, Taiwan; 2Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan; 3Royal Women’s Hospital, Department of Nursing, National Cheng Kung University, Tainan, 701, Taiwan; 4Department of Public Health, National Cheng Kung University, Tainan, 701, Taiwan; 5Institute of Internal Medicine, National Cheng Kung University, Tainan, 701, Taiwan; 6College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan; 7School of Population and Global Health, University of Melbourne, Melbourne, Australia; 8Royal Women’s Hospital, Sydney Local Health District, Sydney, Australia; 9Western Sydney Sexual Health Centre, University of Sydney, Australia; 10Melbourne Sexual Health Centre, Melbourne, Australia.

Introduction The prevalence and predictors of high-risk anal human papillomavirus (HPV) types in the study of the prevention of anal cancer (SPANC).

Methods A cross-sectional survey of 17,885 individuals randomly selected from the Taiwan National Health Insurance Research Database (NHIRD, approximately 23 million individuals in total) was conducted. We included all individuals aged 15-79 years, with and without a diagnosis of anal condyloma acuminata (CA, n=15,061), to determine the prevalence of high-risk HPV (HR-HPV) types (16, 18, 31, 33, 35, 39, 45, 51, 52 and 58) and to explore their association with CA.

Results The overall prevalence of HR-HPV was 37.2% (95% CI: 36.6–37.8). The most common types were 16 (9.3%), 18 (9.2%), 31 (7.6%) and 33 (7.6%). The prevalence of HR-HPV was significantly higher in individuals with CA compared to those without CA (54.3% vs 30.1%, p<0.001). After adjusting for age, gender, location and income, HR-HPV was 303.5 (95% CI: 190.5–466.1) times more likely to have incident HIV infection. Other variables associated with incident HIV infection were being a male (aHR = 10.5, 95% CI: 2.4–46.1), being under 30 years of age (aHR = 3.5, 95% CI: 1.9–5.9) and syphilis diagnosis with treatment before HIV infection (aHR = 4.5, 95% CI: 1.0–19.7).

Conclusion CA is associated with elevated incident HIV infection. HIV risk reduction interventions among patients with CA are warranted.

Disclosure of interest statement This study is funded by the Taiwan Ministry of Science (Project ID: 1030087343). All authors declare no conflict of interest.

10.1136/sextrans-2015-052270.440
Abstracts

Introduction HPV causes ~90% of anal cancers, with HPV16 predominating. Gay men, particularly HIV-positive men, are at greatly increased risk of anal cancer. We describe prevalence and predictors of anal canal detection of any HPV, high-risk (hr) HPV and HPV16, in a cohort of Australian gay men.

Methods SPANC is a 3-year community-recruited, prospective study of HIV(+) and HIV(-) gay men aged ≥35 years. At 6-monthly visits participants complete questionnaires, undergo high resolution anoscopy and anal swabs for cytology and HPV genotyping (Roche Linear Array).

Results By December 2014, 482 participants (median age 49.5 years; 31% HIV positive) had attended a baseline visit. The majority (87%) had ≥1 HPV genotype detected, with ~ two thirds (65%) having ≥1 hrHPV detected. HPV16 was detected in 31% of participants. HIV positive participants and younger participants were more likely to have any HPV detected (p = 0.001 and p = 0.033 respectively). The detection of hrHPV in univariate analyses was significantly associated with positive HIV status (p = 0.001), currently smoking (p = 0.014), younger age (p = 0.012), more lifetime male sexual partners (p = 0.003), more lifetime receptive (RAI) and insertive (IAI) anal intercourse (p = 0.037 and p = 0.002 respectively) history of anal chlamydia (p = 0.003), more receptive anal behaviours in the last 6 months, including RAI (p < 0.001); rimming (p < 0.001); fingering (p < 0.001). More frequent recent RAI and rimming and more lifetime IAI with condoms remained significant in multivariate analyses. HPV16 detection among HIV positive participants was four times more likely among men with a last CD4 cell count < 350 (OR 4.00, p = 0.008) and twice as likely among men with a nadir CD4 cell count < 200 (OR 2.12, p = 0.033).

Conclusion Anal HPV was extremely common in this cohort of homosexual men. Prevalent HPV16 was related to low CD4 count in HIV positive men. Receptive anal sexual practices, including rimming and fingering were predictors of hrHPV detection.

Disclosure of interest statement AEG has received honoraria and research funding from CSL Biotherapies, honoraria and travel funding from Merck, and sits on the Australian advisory board for the Gardasil HPV vaccine. CKF has received honoraria, travel funding and research funding from CSL and Merck, sits on the Australian advisory board for the Gardasil HPV vaccine, and owns shares in CSL Biotherapies. SMG has had grant support from CSL Bio and GlaxoSmithKline, and lecture fees from Merck, GlaxoSmithKline and Sanofi Pasteur; in addition, has received funding through her institution to conduct HPV vaccine studies for MSD and GlaxoSmithKline and is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. RJH has received support from CSL Biotherapies and MSD. All other authors declare that they have no conflicts of interest.

Background Our study aims to characterise hepatitis C virus (HCV) epidemiology in Afghanistan, as part of the Middle East and North Africa (MENA) HCV Epidemiology Synthesis Project. The MENA HCV Epidemiology Synthesis Project is an ongoing effort to characterise HCV epidemiology and inform research, policy, and programming priorities in MENA countries.

Methods We systematically reviewed and synthesised HCV prevalence and incidence data following PRISMA guidelines. Meta-analyses using DerSimonian-Laird random effects models with inverse weighting were implemented to estimate HCV prevalence among populations at various risk of HCV infection. A risk of bias assessment was incorporated.

Results Our search identified 48 HCV prevalence and one HCV incidence measures. Our meta-analyses estimated HCV prevalence at 0.7% among the general population (range: 0.0–4.0%); 95% CI: 0.3–1.3%), 31.8% among people who inject drugs.

THE EPIDEMIOLOGY OF HEPATITIS C VIRUS IN AFGHANISTAN: A SYSTEMATIC REVIEW AND META-ANALYSIS

Factors associated with HPV vaccination coverage at school level during HPV vaccine introduction in Thailand

Introduction In 2014, HPV vaccination program was launched to fifth grade female students in Phra Nakhon Si Ayutthaya province in Thailand. The overall HPV vaccination coverage was 91%, but sub-provincial HPV vaccination coverage varied due to multiple factors. This study aimed to explore factors associated with HPV vaccination coverage at school level during the introduction of HPV vaccine to the national immunisation program.

Methods A retrospective cohort study was conducted in Phra Nakhon Si Ayutthaya province, 613 fifth grade female students from 47 schools were surveyed to determine HPV vaccination coverage at school level. Teachers, healthcare workers (HCWs) and students were interviewed using standardised questionnaire to assess their knowledge and attitude about cervical cancer, HPV vaccine and HPV vaccination program. Furthermore, we explored programmatic activities that might affect HPV vaccination performance then conducted the multiple linear regression analysis to determine their relationship to HPV vaccination coverage at school level.

Results HPV vaccination coverage at schools range from 61.5 to 100 percent. Multiple linear regression analysis revealed that “HCWs knowledge that HPV vaccine safety and efficacy was carefully reviewed prior to registration” (B = 42.2, p-value < 0.01) and “HCWs supported HPV vaccine introduction in the national immunisation program” (B = 8.9, p-value = 0.01) related to increasing HPV vaccination coverage, while “providing vaccine information statement (VIS) to parent” showed a negative relationship (B = -7.6, p-value = 0.04). However, there was no evidence that teacher or student knowledge and attitude were related to HPV vaccination coverage at school level.

Conclusion HCWs’ confidence in HPV vaccine efficacy and safety and their support to HPV vaccine as a part of national immunisation program related to better HPV vaccine coverage, however, providing VIS to parents prior to HPV vaccination shown negative impact on HPV vaccination coverage at school level during HPV vaccine introduction.

Disclosure of interest statement This study was supported by the Department of Disease Control, Ministry of Public Health of Thailand. No pharmaceutical grant was received in the development of this study.